Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations.
Expert Rev Anticancer Ther
; 15(6): 715-25, 2015 Jun.
Article
em En
| MEDLINE
| ID: mdl-26035720
ABSTRACT
We performed a meta-analysis to assess whether blood can be substituted for tumor tissue in K-ras mutation testing. PubMed, EMBASE, MEDLINE, and BIOSIS databases were searched. Twenty-three studies including 1261 patients were included. The pooled overall sensitivity, specificity, and concordance rate were 0.69 (95% CI 0.59-0.78), 0.96 (95% CI 0.93-0.97), and 0.86 (95% CI 0.82-0.89), respectively. Subgroup analysis indicated that plasma (sensitivity 0.74; mutation rate 0.34) exhibited superior sensitivity compared with serum (sensitivity 0.45; mutation rate 0.24). We conclude that blood is a suitable substitute for tumor tissue in K-ras mutation testing. K-ras mutation positivity in blood can be used to identify patients who should not receive EGFR monoclonal antibody therapy, but the absence of blood positivity does not necessarily imply negativity.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Genes ras
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Expert Rev Anticancer Ther
Assunto da revista:
NEOPLASIAS
/
TERAPEUTICA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
China